UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 688

Sortiert nach

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

Annals of oncology, 2018-01, Vol.29 (suppl_1), p.i10-i19

2018

Link zum Volltext

Verfügbarkeit prüfen

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Clinical & translational oncology, 2020-07, Vol.22 (7), p.989-1003

2020

Link zum Volltext

Verfügbarkeit prüfen

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

The European respiratory journal, 2011-03, Vol.37 (3), p.624-631

2011

Link zum Volltext

Verfügbarkeit prüfen

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy

Annals of oncology, 2007-03, Vol.18 (3), p.522-528

2007

Link zum Volltext

Verfügbarkeit prüfen

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

Scientific reports, 2022-05, Vol.12 (1), p.8342-8342, Article 8342

2022

Link zum Volltext

Verfügbarkeit prüfen

Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts

Lung cancer (Amsterdam, Netherlands), 2020-08, Vol.146, p.6-11

2020

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-11, Vol.379 (21), p.2040-2051

2018

Link zum Volltext

Verfügbarkeit prüfen

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Annals of oncology, 2017-02, Vol.28 (2), p.270-277

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials

Lung cancer (Amsterdam, Netherlands), 2014-09, Vol.85 (3), p.408-414

2014

Link zum Volltext

Verfügbarkeit prüfen

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

British journal of cancer, 2011-01, Vol.104 (1), p.68-74

2011

Link zum Volltext

Verfügbarkeit prüfen

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Annals of oncology, 2020-06, Vol.31 (6), p.798-806

2020

Link zum Volltext

Verfügbarkeit prüfen

Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients

Clinical & translational oncology, 2020-08, Vol.22 (8), p.1390-1398

2020

Link zum Volltext

Verfügbarkeit prüfen

Systemic chemotherapy in the management of malignant peritoneal mesothelioma

European journal of surgical oncology, 2006-08, Vol.32 (6), p.676-681

2006

Link zum Volltext

Verfügbarkeit prüfen

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

Annals of oncology, 2014-08, Vol.25 (8), p.1475-1484

2014

Link zum Volltext

Verfügbarkeit prüfen

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

Annals of oncology, 2022-05, Vol.33 (5), p.466-487

2022

Link zum Volltext

Verfügbarkeit prüfen

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer

Annals of oncology, 2016-08, Vol.27 (8), p.1573-1579

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Annals of oncology, 2022-11, Vol.33 (11), p.1168-1178

2022

Link zum Volltext

Verfügbarkeit prüfen

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

Annals of oncology, 2017-12, Vol.28 (12), p.2932-2942

2017

Link zum Volltext

Verfügbarkeit prüfen

NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

Annals of oncology, 2016-10, Vol.27, p.vi577-vi577

2016

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

ESMO open, 2022-04, Vol.7 (2), p.100408-100408, Article 100408

2022

Link zum Volltext

Verfügbarkeit prüfen

Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Clinical & translational oncology, 2015-02, Vol.17 (2), p.103-112

2015

Link zum Volltext

Verfügbarkeit prüfen

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

Annals of oncology, 2019-02, Vol.30 (2), p.161-165

2019

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer

ESMO open, 2022-04, Vol.7 (2), p.100399-100399, Article 100399

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

Annals of oncology, 2023-02, Vol.34 (2), p.173-185

2023

Link zum Volltext

Verfügbarkeit prüfen

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

ESMO open, 2021-10, Vol.6 (5), p.100273-100273, Article 100273

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 688

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(681)
Mit Volltextzugriff
(667)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(170)
Life Sciences & Biomedicine
(167)
Humans
(148)
Oncology
(140)
Male
(87)
Female
(79)
Middle Aged
(78)
Aged
(69)
Adult
(67)
Biological And Medical Sciences
(58)
Medical Sciences
(57)
Lung Neoplasms - Drug Therapy
(51)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(50)
Chemotherapy
(47)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(41)
Pharmacology. Drug Treatments
(39)
Lung Cancer
(37)
Tumors
(36)
Antineoplastic Agents
(35)
Treatment Outcome
(35)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients

Systemic chemotherapy in the management of malignant peritoneal mesothelioma

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

Suchergebnisse filtern